Mission creep, rebates, uncertainty, inertia: the challenges in major HTAs
This article was originally published in Scrip
As a symptom of the impact that registration and reimbursement difficulties in Europe can have, Eisai has decided to make emerging markets such as Russia and Saudi Arabia priorities in the launch of its antiepileptic drug Fycompa (scripintelligence.com, 3 October 2012). With the 10th European Congress on Epileptology now in full swing in London (30 September– 4 October 2012), Gary Hendler, president and CEO of Eisai EMEA & Russia, explained to Scrip how complications in the major European markets had influenced the company's new product launch strategies.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.